Sildenafil reduces Raynaud's frequency in patients with systemic sclerosis

Wednesday, March 9, 2011 - 13:40 in Health & Medicine

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud's phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor or moderate side effects. Full findings are available in the March issue of Arthritis and Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR)...

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net